Kidney disease research supported by the Department of Defense

Sorin Fedeles, PhD, MBA, Adjunct Assistant Professor of Internal Medicine (Nephrology) at Yale School of Medicine, received an Investigator Initiated Research Award from the Department of Defense, for a project titled “Inhibition of the Ire1alpha-XBP1 Pathway Using Toyocamycin has a new way to inhibit the progression of autosomal dominant polycystic kidney and liver disease.”

The research focuses on autosomal dominant polycystic kidney disease (ADPKD). Polycystic kidney disease is one of 42 thematic areas of the department’s peer-reviewed medical research program (PRMRP). ADPKD is a disease in which tubule-derived cysts form and grow in the kidneys for decades, ultimately leading to destruction of renal architecture and function and end-stage renal failure. Fedeles aims to use genetic inhibition of the Ire1α-XBP1 pathway, coupled with chemical inhibition of Ire1α via toyocamycin (previously used in a clinical trial), to slow the growth of cysts by selectively destroying the mutant cells that cause them. form.

The grant period runs from December 2021 to November 2025. Much of the selection process relies heavily on ratings and assessments from scientific peer review committees.

This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the. Peer-reviewed medical research program under award number W81XWH-22-1-005. The opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.

Submitted by Robert Forman on January 13, 2022

Comments are closed.